USPTO serial 79036313
CERVIDX
Reviewed by CopyMark Law Group
Reg. 3476787Status 404
- Filing date
- Status date
- Registration date
- Jul 29, 2008
- Examiner
- BRODY, DANIEL S
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CERVIDX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations and reagents for detection of cancerous conditions, neoplastic conditions, inflammatory conditions, infectious conditions, degenerative conditions, genetically aberrant or diseased conditions, proliferatively aberrant or diseased conditions, vascular disease conditions, premalignant cancerous conditions, malignant cancerous conditions, cancer and inborn deficiencies for scientific or research use | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical preparations for the treatment and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases and for the treatment of premalignant and malignant cancerous conditions, cancer and inborn deficiencies; veterinary preparations for the treatment and prevention of neoplastic, inflammatory, infectious, degenerative, genetic and proliferative and vascular diseases and for the treatment of premalignant and malignant cancerous, conditions, cancer and inborn deficiencies in livestock, cattle, pigs, horses, deer, elk, moose, sheep, dogs, cats, mice, rats, monkeys, apes and birds; medical diagnostic reagents for detection of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases and for the detection of premalignant and malignant cancerous conditions, cancer and inborn deficiencies; medical diagnostic preparations, namely, in-vitro and in-vivo diagnostic preparations, diagnostic immunocytochemical preparations, diagnostic immunohistochemical preparations, diagnostic histology preparations, diagnostic cytology preparations, diagnostic liquid-immuno-assay preparations, diagnostic solid-phase immuno-assay preparations, diagnostic testing strips, diagnostic dip-stick tests, diagnostic preparations for use at point of care, diagnostic lateral-flow assay preparations, diagnostic flow-through assay preparations, diagnostic immuno-chromatographic preparations; diagnostic equipment for medical purposes, namely, strips, cotton sticks, swabs, cotton and tampons for use in sampling, storing, transporting, preparing, enriching, concentrating, testing, analyzing and evaluating of biological material and samples in connection with early diagnosis, diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn deficiencies as indicated above | SECTION 71 - CANCELLED | — |
| 009 | Laboratory equipment for diagnostic purposes, namely, test tubes, multiwell test plates, multiwell ELISA (enzyme linked immunosorbent assay) plates and chromatography columns for use in sampling, storing, transporting, preparing, enriching, concentrating, testing, analyzing and evaluating biological material and samples | SECTION 71 - CANCELLED | — |
| 010 | Medical diagnostic testing machines, namely, point-of-care testing machines, diagnostic liquid-immuno-assay machines, diagnostic immunocytochemical machines, diagnostic immunohistochemical machines, diagnostic histology machines, diagnostic cytology machines, diagnostic solid-phase immuno-assay machines, diagnostic ELISA (enzyme linked immunosorbent assay) testing machines, diagnostic immuno-chromatographic machines, all of the aforementioned machines being for use in analyzing and providing diagnostic test results and used in connection with early diagnosis, diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn deficiencies; diagnostic equipment for medical purposes, namely, syringes, needles, brushes, spatulas and sample receptacles for use in sampling, storing, transporting, preparing, enriching, concentrating, testing, analyzing and evaluating of biological material and samples in connection with early diagnosis, diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn deficiencies; diagnostic nucleic acid detection machines for use in analyzing and providing medical diagnostic test results in connection with early diagnosis, diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification and therapy guidance, and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn deficiencies; diagnostic nucleic acid amplification machines for use in analyzing and providing medical diagnostic test results in connection with early diagnosis, diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification and therapy guidance, and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn deficiencies; diagnostic immuno-histology machines for use in analyzing and providing medical diagnostic test results in connection with early diagnosis, diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification and therapy guidance, and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn deficiencies; diagnostic immuno-cytology machines for use in analyzing and providing medical diagnostic test results in connection with early diagnosis, diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification and therapy guidance, and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn deficiencies; medical diagnostic apparatus and instruments, namely, hand-held, table-top and floor-standing centrifugal, gravitational-separating, electrophoretic, chromatographic, conductometric, potentiometric, spectrometric, spectro-photometric, radiologic electromagnetic-resonance, histological, microscopic and in-vivo imaging machines, all for for use in analyzing and providing medical diagnostic test results in connection with early diagnosis, diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification and therapy guidance, and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn deficiencies; automated and non-automated cellular imaging devices for medical use for use in analyzing and providing medical diagnostic test results in connection with early diagnosis, diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification and therapy guidance, and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn deficiencies, automated and non-automated microscopy devices for medical use for use in analyzing and providing medical diagnostic test results in connection with early diagnosis, diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification and therapy guidance, and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn deficiencies, automated and non-automated imaging analysis devices for clinical and medical laboratory use for use in preparing, enriching, concentrating, testing, analysing and evaluating of biological material and samples in connection with early diagnosis, diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn deficiencies | SECTION 71 - CANCELLED | — |
| 042 | Scientific analysis in the fields of chemistry, biology and molecular biology; laboratory research in the field of molecular biology; laboratory research in the fields of pharmaceutics and food technology; providing research in the fields of pharmaceutical, chemical and medical diagnostic research; research and development of pharmaceutical products and substances for others; scientific research in the nature of scientific information research services; chemical, biological, molecular biology and pharmacogenomic analysis services | SECTION 71 - CANCELLED | — |
| 044 | Medical diagnostic services and provision of medical diagnostic information in the field of detection of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn errors; veterinary diagnostic services and provision of veterinary diagnostic information in the field of detection of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn deficiencies in livestock, cattle, pigs, horses, deer, elk, moose, sheep, dogs, cats, mice, rats, monkeys, apes and birds | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by mtm laboratories AG
- Other trademarks owned by mtm laboratories AG
- Other trademarks owned by Roche mtm laboratories AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CERVIDX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 26, 2018 | UNDN | UNDELIVERABLE MAIL - NO ACTION TAKEN | — |
| Sep 20, 2018 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Sep 20, 2018 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Feb 5, 2016 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Jan 14, 2016 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Jan 14, 2016 | INPC | INVALIDATION PROCESSED | — |
| Nov 6, 2015 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Mar 6, 2015 | C71T | CANCELLED SECTION 71 | — |
| Dec 30, 2012 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 2, 2012 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Nov 17, 2008 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 17, 2008 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 29, 2008 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 29, 2008 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 20, 2008 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Feb 13, 2008 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Feb 5, 2008 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 16, 2008 | NPUB | NOTICE OF PUBLICATION | — |
| Jan 3, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jan 3, 2008 | ALIE | ASSIGNED TO LIE | — |
| Nov 15, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 15, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 15, 2007 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 15, 2007 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 15, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 15, 2007 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 13, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 13, 2007 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 13, 2007 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 1, 2007 | RFNP | REFUSAL PROCESSED BY IB | — |
| May 11, 2007 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 11, 2007 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 3, 2007 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 2, 2007 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 27, 2007 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 27, 2007 | NWAP | NEW APPLICATION ENTERED | — |
| Apr 26, 2007 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |